Unfortunately, there are no hard and fast answers given the problems have developed over time, but in my opinion it wouldn't hurt for management, going forward to...
- try and shore up its major holders by acting as a middleman, linking up interested buyers with platinum to arrange an orderly block trade for remaining shares at an agreeable price. The recent drop makes this less likely as Platinum CP would be 6c from previous raise unless L1 (who i read somewhere now own a majority stake in Platinum) are really putting the boots in to de-leverage from the sector.
- restrictions in future cap raises preventing sale prior to any key milestones (eg: Phase III read out etc) or ... heaven forbid, throw retail holders a bone and allow an annual SPP in conjunction with a cap raise for instos. Same escrow requirements etc but its an annual thing that will provide a type of lifeline funding to the company but moreso to give retailers something in return for loyalty.
- Partnership with major pharma whereby we take a hit in terms of future licencing revenue or IP ownership stake in order to lock in funding and manufacturing/ distribution/ marketing structures for commercialisation should things go to plan.
- be firm with timelines and messaging relating to progress, developments, outcomes. So much hype and nothing comes from it gets old quickly.
Thats just off the top of my head, but i am coming from an uniformed position with regards risk parameters etc but i just have this feeling not enough is being done to either get the best deal or at the very least COMMUNICATE to holders why this is the best we can get!!
Add to My Watchlist
What is My Watchlist?
